Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma
Clinical trial NCT07601100 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07601100
- Sponsor
- Dana-Farber Cancer Institute
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-26
- Primary completion
- 2029-07-01
- Enrollment
- 88
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.